346 related articles for article (PubMed ID: 22024782)
1. An evaluation of inhaled bronchodilator therapy in patients hospitalized for non-life-threatening COPD exacerbations.
Woods JA; Usery JB; Self TH; Finch CK
South Med J; 2011 Nov; 104(11):742-5. PubMed ID: 22024782
[TBL] [Abstract][Full Text] [Related]
2. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
Blais L; Forget A; Ramachandran S
Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
[TBL] [Abstract][Full Text] [Related]
3. Treatment of patients hospitalized for exacerbations of chronic obstructive pulmonary disease: comparison of an oral/metered-dose inhaler regimen and an intravenous/nebulizer regimen.
Shortall SP; Blum J; Oldenburg FA; Rodgerson L; Branscombe JM; Harrow EM
Respir Care; 2002 Feb; 47(2):154-8. PubMed ID: 11812271
[TBL] [Abstract][Full Text] [Related]
4. Nebulized formoterol effect on bronchodilation and satisfaction in COPD patients compared to QID ipratropium/albuterol MDI.
Sutherland ER; Brazinsky S; Feldman G; McGinty J; Tomlinson L; Denis-Mize K
Curr Med Res Opin; 2009 Mar; 25(3):653-61. PubMed ID: 19232039
[TBL] [Abstract][Full Text] [Related]
5. Quality of life measurements and bronchodilator responsiveness in prescribing nebulizer therapy in COPD.
Brophy C; Kastelik J; Gardiner E; Greenstone M
Chron Respir Dis; 2008; 5(1):13-8. PubMed ID: 18303097
[TBL] [Abstract][Full Text] [Related]
6. A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation.
Sharafkhaneh A; Altan AE; Colice GL; Hanania NA; Donohue JF; Kurlander JL; Rodriguez-Roisin R; Altman PR
Respir Med; 2014 Sep; 108(9):1310-20. PubMed ID: 25130680
[TBL] [Abstract][Full Text] [Related]
7. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
8. Delivery of ipratropium and albuterol combination therapy for chronic obstructive pulmonary disease: effectiveness of a two-in-one inhaler versus separate inhalers.
Chrischilles E; Gilden D; Kubisiak J; Rubenstein L; Shah H
Am J Manag Care; 2002 Oct; 8(10):902-11. PubMed ID: 12395958
[TBL] [Abstract][Full Text] [Related]
9. Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis.
Fitch K; Iwasaki K; Pyenson B; Plauschinat C; Zhang J
Curr Med Res Opin; 2011 Jul; 27(7):1425-9. PubMed ID: 21599554
[TBL] [Abstract][Full Text] [Related]
10. The role of domiciliary nebulizers in managing patients with severe COPD.
Eiser N; Angus K; McHale S
Respir Med; 2001 Apr; 95(4):265-74. PubMed ID: 11316108
[TBL] [Abstract][Full Text] [Related]
11. Automatic replacement of albuterol nebulizer therapy by metered-dose inhaler and valved holding chamber.
Hendeles L; Hatton RC; Coons TJ; Carlson L
Am J Health Syst Pharm; 2005 May; 62(10):1053-61. PubMed ID: 15901590
[TBL] [Abstract][Full Text] [Related]
12. Salbutamol with metered dose inhalers with spacers - an established emergency treatment for preschool wheeze.
Mecklin M; Paassilta M; Korppi M
Acta Paediatr; 2012 Nov; 101(11):1161-3. PubMed ID: 22897230
[TBL] [Abstract][Full Text] [Related]
13. Ipratropium treatment of acute airways disease.
Peterson GM; Boyles PJ; Bleasel MD; Vial JH
Ann Pharmacother; 2003 Mar; 37(3):339-44. PubMed ID: 12639159
[TBL] [Abstract][Full Text] [Related]
14. The conversion to metered-dose inhaler with valved holding chamber to administer inhaled albuterol: a pediatric hospital experience.
Salyer JW; DiBlasi RM; Crotwell DN; Cowan CA; Carter ER
Respir Care; 2008 Mar; 53(3):338-45. PubMed ID: 18291050
[TBL] [Abstract][Full Text] [Related]
15. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
[TBL] [Abstract][Full Text] [Related]
16. A review and economic evaluation of bronchodilator delivery methods in hospitalized patients.
Turner MO; Gafni A; Swan D; FitzGerald JM
Arch Intern Med; 1996 Oct; 156(18):2113-8. PubMed ID: 8862104
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI.
Zuwallack R; De Salvo MC; Kaelin T; Bateman ED; Park CS; Abrahams R; Fakih F; Sachs P; Pudi K; Zhao Y; Wood CC;
Respir Med; 2010 Aug; 104(8):1179-88. PubMed ID: 20172704
[TBL] [Abstract][Full Text] [Related]
18. Daily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover study.
Singh D; Zhu CQ; Sharma S; Church A; Kalberg CJ
Pulm Pharmacol Ther; 2015 Apr; 31():85-91. PubMed ID: 25197005
[TBL] [Abstract][Full Text] [Related]
19. Guideline for the management of chronic obstructive pulmonary disease--2011 update.
Abdool-Gaffar MS; Ambaram A; Ainslie GM; Bolliger CT; Feldman C; Geffen L; Irusen EM; Joubert J; Lalloo UG; Mabaso TT; Nyamande K; O'Brien J; Otto W; Raine R; Richards G; Smith C; Stickells D; Venter A; Visser S; Wong M;
S Afr Med J; 2011 Jan; 101(1 Pt 2):63-73. PubMed ID: 21526617
[TBL] [Abstract][Full Text] [Related]
20. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
Hagedorn C; Kässner F; Banik N; Ntampakas P; Fielder K
Respir Med; 2013 Apr; 107(4):542-9. PubMed ID: 23337300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
